Trials / Completed
CompletedNCT01635777
Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- AB Foundation · Academic / Other
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Miltefosine efficacy will be \>85%
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Miltefosine | 2.5 mg/kg/day for 12 weeks |
| DRUG | Miltefosine | 2.5 mg/kg/day for 8 weeks |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2009-10-01
- Completion
- 2010-12-01
- First posted
- 2012-07-10
- Last updated
- 2012-07-10
Locations
1 site across 1 country: India
Source: ClinicalTrials.gov record NCT01635777. Inclusion in this directory is not an endorsement.